METAMINER PARTNERSHIPS

DISEASE-FOCUSED COLLABORATIONS TO ACCELERATE YOUR RESEARCH



USE METAMINER PARTNERSHIPS FOR

- Manual annotation of all gene-disease associations at DNA, RNA and protein level - SNPs, mutations, splice variants, PTMs etc.
- Reconstruction of disease pathways, i.e. specific gain and loss of function changes not happening in normal cells
- Functional data and knowledge mining of OMICs experimental studies published in a disease area, such as GWAS, whole-genome re-sequencing and global gene expression

BENEFITS

- Get early access to new pathway maps that do not exist anywhere – giving you a competitive edge
- Speed up your discovery pipeline by having access to biomarker and drug repositories
- Create opportunities to develop and test hypotheses
- Direct and prioritize your efforts with intelligent pathways data
- Gain a faster and easier understanding of the whole disease, rather than just your niche interest

Accelerate your research and discovery by collaborating with a *MetaMiner Partnership*: your expert knowledge and ideas, our highly specialized expertise in manual curation and disease map development to create new pathways quickly.

MetaMiner Partnerships give organizations like yours an opportunity to rapidly progress your research with single or multi-year, disease focused collaborations. Your expert knowledge and ideas combined with our highly specialized expertise in manual curation and disease map development fit together to create a disease specific pathway platform with biomarkers and therapeutics and a systems-based analysis tool.

As well as working with a group of partners, we also offer exclusive partnerships solely with your company: you direct our research efforts to find information on the pathways, disease, and themes that interest you.

With a *MetaMiner Partnership*, you gain access to:

- An established rigorous and successful manual curation process
- A team of annotators who are disease specialists dedicated to surveying the literature
- A team of high throughput data analysis for the data repository
- A team of signaling mechanism and map creators
- A collaborative environment with other scientists around the world

CONTENT

A fundamental understanding of human diseases is necessary for successful disease research, drug and biomarker discovery, translational medicine, and personalized health. Diseases represent abnormal states of normal human systems, impacting dozens of processes and pathways. But reconstruction of disease mechanisms is a far from trivial endeavour, requiring technology and state-of-the-art domain expertise.

Using a unique language to allow the inclusion of proteins (including fusion proteins, complexes, and isoforms), RNA, DNA, microRNA, and small molecules, and renowned for quality manually-curated content, on average we develop 12 step pathways and currently have the largest pathway map collection in the world, more than 1,000. Along with 12 (and counting) ontologies, you can ask complicated questions of our content and get the answers your research needs.

Gain access to manually-curated true multi-step pathway maps backed by small experiment evidence. Current partnerships include:

- CNS
- Cystic Fibrosis
- Dry Eye
- Mechanism of Action
- Metabolic Diseases
- Obesity
- Oncology
- Respiratory
- Skin
- Stem Cells
- Toxicology

After a period of exclusivity the pathways developed through the partnerships are made available as modules of our data-mining and pathway analysis solution, *MetaCore*™. Current *MetaCore* modules include: Gastric Cancer; Hepatocellular Carcinoma, Huntington's Disease, Pancreatic Cancer, Prostate Cancer, and Stem Cells.



Completed prostate cancer map with particular focus on prolactin signalling. The disease specific annotations are marked in magenta.

FEATURES

MetaMiner Partnerships give you a systematic approach to disease reconstruction based on three pillars:

- Manual annotation of compound-disease, and gene-disease associations at DNA, RNA and protein level.
- Reconstruction of disease pathways, i.e. specific gain and loss of function changes.
- Development of a data repository of statistically analysed OMICs studies.

METAMINER PARTNERSHIPS: THE CONCEPT



THOMSON REUTERS REGIONAL OFFICES

North America
Philadelphia +1 800 336 4474
+1 215 386 0100

Latin America
+55 11 8370 9845

Europe, Middle East and Africa
Barcelona +34 93 459 2220
London +44 20 7433 4000

Asia Pacific
Singapore +65 6775 5088
Tokyo +81 3 5218 6500

For a complete office list visit:
ip-science.thomsonreuters.com/contact

Contact us to find out more about *MetaMiner Partnerships* or visit thomsonreuters.com/diseaseinsight

LS0611234

THOMSON REUTERS™